YU88702A - NOVI OBLICI MEZOPROGESTIN 11Гџ-[4E(HIDROKSIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17Гџ-METOKSI-ESTRA-4,9-DIEN-3-ONA U ČVRSTIM FAZAMA - Google Patents

NOVI OBLICI MEZOPROGESTIN 11Гџ-[4E(HIDROKSIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17Гџ-METOKSI-ESTRA-4,9-DIEN-3-ONA U ČVRSTIM FAZAMA

Info

Publication number
YU88702A
YU88702A YU88702A YUP88702A YU88702A YU 88702 A YU88702 A YU 88702A YU 88702 A YU88702 A YU 88702A YU P88702 A YUP88702 A YU P88702A YU 88702 A YU88702 A YU 88702A
Authority
YU
Yugoslavia
Prior art keywords
solid body
body forms
novel solid
mesoprogestin
hydroxyiminomethyl
Prior art date
Application number
YU88702A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Muller
Gabriele Winter
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU88702A publication Critical patent/YU88702A/sh
Publication of RS50493B publication Critical patent/RS50493B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pronalazak se odnosi na nove oblike čvrstih faza mezoprogestin 11Гџ-[4E-hidroksiiminometil)fenil]-17α-metoksimetil-17Гџ-metoksi-estra-4,9-dien-3-ona (oksim J 867), posebno krajnje čistog i stabilnog amorfnog ili krajnje kristalnog oblika (ansolvat/anhidrat) jedinjenja J 867, postupak za njihovu proizvodnju kao njihovu upotrebu u farmaceutskim sastavima. Novi oblici čvrstih faza se ističu posebno sa visokom stabilnošću. Oblici čvrstih faza oksima J 867 mogu se upotrebiti posebno kod kontrole radjanja i terapije zamene hormona.[The invention relates to novel solid body forms of mesoprogestin 11Гџ-[4E-(hydroxyiminomethyl)-phenyl]-17α-methoxymethyl- 17Гџ-methoxy-estra-4,9-dien-3-one (oxime J 867), particularly a highly pure and stable amorphous or highly crystalline form (ansolvate/anhydrate) of compound J 867. The invention also relates to methods for producing said novel solid body forms and to the use thereof in pharmaceutical compositions. The novel solid body forms are characterized by exhibiting a high degree of stability. The solid body forms of oxime J 867 can, in particular, be used in the area of fertility control and in hormone replacement therapy.
YUP-887/02A 2000-05-23 2001-05-09 NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON RS50493B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on

Publications (2)

Publication Number Publication Date
YU88702A true YU88702A (sh) 2006-01-16
RS50493B RS50493B (sr) 2010-03-02

Family

ID=8168805

Country Status (30)

Country Link
US (1) US7799770B2 (sh)
EP (3) EP1157996A1 (sh)
JP (1) JP2003534350A (sh)
KR (1) KR100553292B1 (sh)
CN (1) CN100384867C (sh)
AT (1) ATE397617T1 (sh)
AU (2) AU2001256344B2 (sh)
BG (1) BG65968B1 (sh)
BR (1) BR0111058A (sh)
CA (1) CA2409869C (sh)
CZ (1) CZ2003620A3 (sh)
DE (1) DE50114012D1 (sh)
DK (1) DK1292607T3 (sh)
EA (1) EA005623B1 (sh)
EC (2) ECSP024358A (sh)
ES (1) ES2307613T3 (sh)
HR (2) HRP20021032B1 (sh)
HU (1) HUP0301956A3 (sh)
IL (2) IL152868A0 (sh)
ME (1) MEP15608A (sh)
MX (1) MXPA02011524A (sh)
NO (1) NO327004B1 (sh)
NZ (1) NZ522768A (sh)
PL (1) PL358789A1 (sh)
PT (1) PT1292607E (sh)
RS (1) RS50493B (sh)
SK (1) SK2922003A3 (sh)
UA (1) UA73988C2 (sh)
WO (1) WO2001090137A2 (sh)
ZA (1) ZA200209322B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2006078731A2 (en) * 2005-01-18 2006-07-27 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
US20090054387A1 (en) 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
ZA200209322B (en) 2005-03-10
ECSP084358A (es) 2008-11-27
EP1862469A2 (de) 2007-12-05
NO20025613D0 (no) 2002-11-22
CA2409869C (en) 2009-02-03
HUP0301956A2 (hu) 2003-09-29
DK1292607T3 (da) 2008-10-13
NZ522768A (en) 2005-03-24
PL358789A1 (en) 2004-08-23
BG65968B1 (bg) 2010-07-30
JP2003534350A (ja) 2003-11-18
EA200201192A1 (ru) 2003-06-26
AU2001256344B8 (en) 2001-12-03
CA2409869A1 (en) 2002-11-20
HUP0301956A3 (en) 2010-03-29
AU5634401A (en) 2001-12-03
ECSP024358A (es) 2003-03-31
MEP15608A (en) 2010-06-10
SK2922003A3 (en) 2003-08-05
MXPA02011524A (es) 2004-09-10
US20040006241A1 (en) 2004-01-08
KR100553292B1 (ko) 2006-02-22
ATE397617T1 (de) 2008-06-15
UA73988C2 (en) 2005-10-17
IL152868A (en) 2009-08-03
ES2307613T3 (es) 2008-12-01
CN100384867C (zh) 2008-04-30
DE50114012D1 (en) 2008-07-17
HRP20021032B1 (en) 2008-09-30
WO2001090137A2 (de) 2001-11-29
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
EP1157996A1 (de) 2001-11-28
WO2001090137A3 (de) 2002-04-04
IL152868A0 (en) 2003-06-24
PT1292607E (pt) 2008-09-15
EP1292607B1 (de) 2008-06-04
NO20025613L (no) 2002-11-22
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
RS50493B (sr) 2010-03-02
EP1292607A2 (de) 2003-03-19
BR0111058A (pt) 2003-04-15
EA005623B1 (ru) 2005-04-28
HRP20080423A2 (en) 2008-10-31
US7799770B2 (en) 2010-09-21
HRP20021032A2 (en) 2005-02-28
NO327004B1 (no) 2009-04-06
KR20030028742A (ko) 2003-04-10

Similar Documents

Publication Publication Date Title
YU88702A (sh) NOVI OBLICI MEZOPROGESTIN 11Гџ-[4E(HIDROKSIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17Гџ-METOKSI-ESTRA-4,9-DIEN-3-ONA U ČVRSTIM FAZAMA
MY140674A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
PL367094A1 (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
NZ514711A (en) Compounds useful as anti-inflammatory agents
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
CZ258896A3 (en) Morpholine derivatives, process of their preparation and pharmaceutical compositions containing thereof
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
HUP0103494A2 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
AU2323897A (en) Cyclopropyl alkanoic acid derivatives
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
CA2420177A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
CA2429639A1 (en) Stable azithromycin monohydrate
IL139861A (en) 17beta-AMINO-AND HYDROXYLAMINO -11 beta - ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
BG107407A (en) Novel polymorph v of torasemide
AU2566101A (en) Compounds and methods for the treatment of pain
RS107004A (en) 9-alpha-substituted estratrienes as selectively active estrogen
YU70502A (sh) Amorfna modifikacija torasemida
GB0108903D0 (en) Novel crystalline forms of a factor Xa inhibitor
GB0019008D0 (en) Therapeutic compounds
HU0102118D0 (en) Process for chloromethylation
HK1044542A1 (en) 11-Beta-aryl-17, 17-spirothiolane-substituted steroids.
PL370479A1 (en) Hexacyclic compounds
AU2002210537A1 (en) (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists